Crescent Biopharma, Inc.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Curon Biopharmaceutical is a clinical-stage biotechnology company developing antibody-based medicines, including bispecific antibodies, for cancer and other serious diseases. It serves patients and healthcare providers through the development of therapeutic biologics, with programs intended for oncology and immunology applications.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from human papillomavirus. Beyond its flagship program, Cue Biopharma is also developing a range of other innovative platforms: CUE-102, another fusion protein biologic designed to stimulate specific T cells to combat cancer; CUE-103, an Immuno-STAT from the CUE-100 series, which is developed to target the KRAS G12V mutation relevant in diseases like colorectal, lung, and pancreatic cancers; CUE-200, which concentrates on cell surface receptors such as CD80 and/or 4-1BBL to counteract T cell exhaustion often seen in chronic infections; and the CUE-300 and CUE-400 frameworks, conceptual platforms aimed at treating diverse autoimmune conditions. Cue Biopharma maintains key strategic alliances, including collaborations with Merck Sharp & Dohme Corp. for the research and development of its unique biologics targeting autoimmune indications, with LG Chem Life Sciences for advancing Immuno-STATs in the field of oncology, and with the Albert Einstein College of Medicine. The company, founded in 2014, was initially known as Imagen Biopharma, Inc. before adopting its current name, Cue Biopharma, Inc., in October 2016. It is headquartered in Cambridge, Massachusetts.

Abpro Holdings, Inc. is a biotechnology firm specializing in the creation of innovative antibody treatments, primarily targeting immuno-oncology and ophthalmology. The company leverages two proprietary technological platforms: DiversImmune, a discovery platform that identifies a broad spectrum of unique antibodies against both established and emerging therapeutic targets, and MultiMab, an engineering platform offering the versatility to assemble antibody components into customized, multi-specific constructs tailored for specific therapeutic needs. Abpro's flagship therapeutic pipeline includes ABP-102, a next-generation immuno-oncology TetraBi antibody engineered to dually target HER2 and CD3, offering a potential treatment for HER2-positive solid tumors like breast and gastric cancers. Another key candidate, ABP-201, is a TetraBi antibody designed to simultaneously inhibit both VEGF and ANG-2 pathways for the management of vascular eye diseases, such as diabetic macular edema and wet age-related macular degeneration. The company's pipeline also features ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, another TetraBi antibody focused on claudin 18.2 and CD3 for gastric cancers. Abpro maintains strategic alliances with Celltrion Inc. and Abpro Bio International, Inc. Established in 2004, Abpro Holdings, Inc. is headquartered in Woburn, Massachusetts.

Crossbow Therapeutics is a privately held biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company develops potent antibody therapeutics aimed at expanding treatment options and combating cancer.

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.